Health Tech of the Week: Biotts Technology breaks skin barriers – a new era of pharmacotherapy

Spring is the time when we start wearing more revealing clothes, which can expose us to minor skin injuries. Together with the HealthTech of the Week team, we found this the perfect moment to introduce the Polish biotech company Biotts. The company has developed an innovative technology that effectively penetrates medicinal substances through the skin, eliminating the need for injections and tablets. Thanks to the patented MTC-Y™ carrier, it is now possible to deliver even large active molecules, opening new therapeutic possibilities in diabetology, oncology, and cardiology.

What caught our attention about Biotts is its development of a unique transdermal drug delivery system that surpasses the boundaries set by classical pharmacology. Founded in 2018 by Dr. Jan Meller, Konrad Krajewski, and his associate, the company was born out of a desire to verify academic claims about the limitations of transporting active substances through the skin. Traditionally, it was believed that the skin is an impermeable barrier for molecules weighing more than 500 Da. The Biotts team disproved this assumption by developing a carrier that allows the transport of substances with a mass of up to 6000 Da, opening entirely new possibilities in pharmacology.

The company’s key asset is its patented MTC-Y™ carrier, a mixture of substances that enable transdermal transport of both lipophilic and hydrophilic molecules. This system allows active substances to effectively penetrate the skin without causing irritation, ensuring stable and precise drug delivery. One of its major advantages is the ability to create multi-component transdermal formulations, supporting combination therapies. It also increases the bioavailability of active substances, which can lead to a reduction in drug dosages while maintaining effectiveness. Additionally, it minimizes side effects, particularly those affecting the digestive system, and enhances patient comfort by eliminating the need for injections or tablets.

Biotts’ technology has applications in various therapeutic fields. In addition to diabetology—where intensive research on transdermal insulin is underway—the company is focusing on cardiology, exploring solutions for transdermal delivery of blood pressure and heart rhythm-regulating drugs.

– We are also working on a carrier that delivers active substances used in the treatment of breast cancer, as well as pain management solutions that enable more effective and controlled dosing of analgesics – says Paweł Biernat, CTO of Biotts.

Why is this so important?

The introduction of transdermal drug delivery systems brings significant economic and clinical benefits. By increasing the bioavailability of active substances, pharmaceutical raw materials can be used more efficiently, reducing drug production costs. Furthermore, the transdermal route minimizes the need for single-use medical equipment such as needles and syringes, which is particularly crucial in developing countries where hygiene and sterility pose major challenges.

Patients also benefit from avoiding painful injections, which is especially important for chronic treatments like diabetes. The discretion and convenience of transdermal systems improve treatment adherence—a key factor in therapeutic success.

Despite promising research results, introducing new transdermal drugs comes with regulatory challenges. Unlike the well-established registration procedures for oral and injectable drugs, transdermal products require additional studies and adaptations to meet the requirements of various regulatory agencies. Biotts aims to obtain registration through an accelerated or hybrid pathway, which could significantly lower the cost of bringing the product to market.

The future of transdermatology

The company is actively expanding internationally, opening a Biotts US branch to establish strategic collaborations with global pharmaceutical corporations. Presence in the American market is a key element of its development strategy, potentially accelerating regulatory approvals and commercializing new products. Over the next five years, Biotts plans to continue research on transdermal insulin, develop innovative oncological therapies, and launch the first phase of clinical trials for additional products.

– Our long-term goal is to create a comprehensive platform for transdermal drug delivery that will revolutionize the treatment of many chronic diseases and provide patients worldwide with more effective and convenient therapies – emphasizes the company’s CTO.

Biotts exemplifies a biotech company that combines cutting-edge scientific research with real-world impact on the future of pharmacotherapy. Thanks to its innovative MTC-Y™ technology and the determination of its research team, it has created a solution that could significantly improve patients’ quality of life and optimize healthcare costs on a global scale. As transdermal technologies continue to evolve, Biotts has the potential to become a leader in modern drug delivery, setting new standards in personalized medicine and 21st-century pharmacy. We believe this won’t be the last we hear of them!

—

Stay tuned for more in the “Health Tech of the Week” series, where we’ll continue to uncover fascinating stories from the world of medical technologies that are changing the face of healthcare. If you’re working on an innovative project in the field of new technologies and medicine or want to recommend an interesting solution, contact us at: [email protected].